Medscape

FDA Asks for Drug Interaction Studies on Kayexalate

The US Food and Drug Administration (FDA) has asked the maker of sodium polystyrene sulfonate (Kayexalate), Concordia Pharmaceuticals, to conduct studies of the drug's potential to interact with other ...
Monthly Prescribing Reference

New Drug Approval Leads FDA to Issue Alert for Similar Products

The Food and Drug Administration (FDA) announced that it will require the manufacturer of Kayexalate (sodium polystyrene sulfonate; Concordia Pharmaceuticals) to conduct studies on drug-drug ...
Nature

Necrotizing enterocolitis in a 850 gram infant receiving sorbitol-free sodium polystyrene sulfonate (Kayexalate): clinical and histopathologic findings

We report a 27-week, 850 g infant with severe Streptococcus group B sepsis and life-threatening hyperkalemia due to progressive anuria. On the fourth day of life, after he failed treatment with ...
FiercePharma

Bourne Partners and Cerberus Capital Portfolio Company, Covis Pharma, Acquires US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®

Bourne Partners and Cerberus Capital Portfolio Company, Covis Pharma, Acquires US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate® ZUG Switzerland (April 4, 2013) - ...